Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study
The Oncologist · 2023
DOI: 10.1093/oncolo/oyad017 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2023. Verfasst von Ari Pelcovits und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Alpert Medical School of Brown University, Providence, RI, USA. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Newly diagnosed multiple myeloma patients have many available treatment options. While lenalidomide, bortezomib, and dexamethasone (RVD) is the preferred initial treatment for many patients, several other agents may provide similar efficacy with less toxicity and improved ease of administration.
Methods
We evaluated the safety and efficacy of the all-oral regimen of ixazomib, cyclophosphamide, and dexamethasone with the use of metronomic cyclophosphamide dosing in the treatment of patients with newly diagnosed multiple myeloma.
Results
The study was stopped prior to planned enrollment due to slow recruitment, with 12 patients available for final analysis. The overall response rate was 58.3% with 2 patients achieving a very good partial response (16.7%) and 5 patients achieving a partial response (41.7%). Median progression-free survival was 16 months, and median overall survival was 43 months. There were no episodes of grade 3 or greater peripheral neuropathy. Grade 3 or greater dermatologic toxicity was experienced in 50% of patients.
Conclusion
Although limited enrollment prevented full efficacy evaluation, our data do not support further study of metronomic cyclophosphamide in combination with ixazomib and dexamethasone in the treatment of newly diagnosed multiple myeloma. The activity of this regimen in the relapsed/refractory setting requires further study (ClinicalTrials.gov Identifier: NCT02412228).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Alpert Medical School of Brown University, Providence, RI, USA.
- Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI, USA.
- Division of Adult Leukemia, Dana-Farber Cancer Center, Boston, MA, USA.
ORCID-Profile: Ari Pelcovits
Zitieren
APA
Pelcovits, A., Barth, P., Reagan, J. L., Olszewski, A. J., Rosati, V., Wood, R., Sturtevant, A., & Winer, E. S. (2023). Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study. The Oncologist. https://doi.org/10.1093/oncolo/oyad017
Vancouver
Pelcovits A, Barth P, Reagan JL, Olszewski AJ, Rosati V, Wood R, et al. Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study. The Oncologist. 2023. doi:10.1093/oncolo/oyad017
BibTeX
@article{Pelcovits2023,
author = {Pelcovits, Ari and Barth, Peter and Reagan, John L and Olszewski, Adam J and Rosati, Vallerie and Wood, Roxanne and Sturtevant, Ashlee and Winer, Eric S},
title = {Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study},
journal = {The Oncologist},
year = {2023},
doi = {10.1093/oncolo/oyad017}
}
EUVIMED